According to Tufts Center for the Study of Drug Development, the average time to build and release a clinical study database is more than 73 days and the average time to lock data at the end of a trial is nearly 39 days.
In 2017, Vertex Pharmaceuticals addressed this issue head-on by setting aggressive internal targets. The company has since reduced database build and release times from 12-14 weeks to six to eight, and data lock times from 22 days to just 15.
On 27/02/2020 mesoblast announced in their half year results.
"The Phase 3 trial of REVASCOR® for advanced chronic heart failure surpassed the number of primary
endpoint events required for trial completion. "
Using the 12-14 weeks time frame we are about due to receive data.
Hold on for the ride.
Glta
Fishywoo
REVASCOR® for advanced chronic heart failure
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.025(2.38%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.06 | $1.06 | $1.02 | $5.734M | 5.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 203347 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 125348 | 6 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
-0.025 ( 2.94 %) |
||||
| Open | High | Low | Volume | ||
| $1.06 | $1.06 | $1.02 | 953870 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| MSB (ASX) Chart |